Table of Contents

company-logo

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Atara Biotherapeutics Dividend Announcement

• Atara Biotherapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Atara Biotherapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Atara Biotherapeutics Dividend History

Atara Biotherapeutics Dividend Yield

Atara Biotherapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Atara Biotherapeutics stock? Use our calculator to estimate your expected dividend yield:

Atara Biotherapeutics Financial Ratios

P/E ratio-0.10
PEG ratio0.00
P/B ratio-1.06
ROE965.52%
Payout ratio0.00%
Current ratio0.59
Quick ratio0.50
Cash Ratio0.30

Atara Biotherapeutics Dividend FAQ

Does Atara Biotherapeutics stock pay dividends?
Atara Biotherapeutics does not currently pay dividends to its shareholders.
Has Atara Biotherapeutics ever paid a dividend?
No, Atara Biotherapeutics has no a history of paying dividends to its shareholders. Atara Biotherapeutics is not known for its dividend payments.
Why doesn't Atara Biotherapeutics pay dividends?
There are several potential reasons why Atara Biotherapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Atara Biotherapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Atara Biotherapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Atara Biotherapeutics a dividend aristocrat?
Atara Biotherapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Atara Biotherapeutics a dividend king?
Atara Biotherapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Atara Biotherapeutics a dividend stock?
No, Atara Biotherapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Atara Biotherapeutics stocks?
To buy Atara Biotherapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Atara Biotherapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.